Systems-Based Solutions for Addressing Treatment Delays in Black Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)

Practice Solutions for Addressing Treatment Delays in Black Patients With Metastatic Castration Resistant Prostate Cancer

Interactive Practice Guide

Outcomes studies have shown that Black men are 70% more likely to develop prostate cancer, have earlier onset and more aggressive disease, and higher rates of morbidity and mortality compared to White men. But recent studies have found that after adjusting for nonbiological factors such as access to care and standardized treatment, Black men with metastatic disease realize more favorable survival benefits when provided equal access to therapy.

While Black men have been underrepresented in clinical trials and less likely to undergo genomic profiling of metastatic prostate cancer, a key opportunity lies with facilitating access to novel therapies, especially for heavily pre-treated patients with metastatic castration resistant prostate cancer (mCRPC). Studies show that Black men diagnosed with more advanced stages of prostate cancer are significantly less likely to be prescribed novel hormone therapy than other racial and ethnic groups.

When considering that the growing number of therapeutic options for prostate cancer already creates challenges for navigating optimal treatment selection and sequencing, finding solutions to mitigate access to novel agents further challenges the implementation of evidence-based medicine into real-world practice. In response, this educational activity has compiled education and practical tools to help you efficiently and effectively bridge these gaps. It also includes downloadable slide decks and discussion guides to initiate meaningful conversations and improve interprofessional care within your team. Drive changes to positively impact care for your patients by ensuring all patients have access to the right therapies at the right time.

Faculty: Russell Z. Szmulewitz, MD, Samuel L. Washington III, MD, MAS, Meghan Catenacci, BSN, RN, MS, Timothy McNichol, LCSW, Rebecca LaRue, PharmD, BCOP

Release Date: July 15, 2025

Expiration Date: July 15, 2026

Systems-Based Solutions for Addressing Treatment Delays in Black Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Digital Quality Improvement

Faculty: Russell Z. Szmulewitz, MD, Samuel L. Washington III, MD, MAS, Meghan Catenacci, BSN, RN, MS, Timothy McNichol, LCSW

Release Date: July 15, 2025

Expiration Date: July 15, 2027